# Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

> **NCT00077844** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 3532 (estimated)

## Conditions studied

- Percutaneous Coronary Intervention

## Interventions

- **DRUG:** Enoxaparin sodium

## Key facts

- **NCT ID:** NCT00077844
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 3532 (ESTIMATED)
- **Last updated:** 2011-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077844, "Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00077844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*